Document:

<PAGE>

                                                                   Exhibit 10.37

                              MYMETICS CORPORATION

                          706 Giddings Avenue, Suite 1C
                         Annapolis, Maryland 21401-1472

                                February 6, 2003

                            DIRECTOR AND NON-EMPLOYEE
                             STOCK OPTION AGREEMENT
                                 (Non-Statutory)

Dr. Peter P. McCann
1669 Chinford Trail
Annapolis, MD  21401

Dear Dr. McCann:

         I am pleased to advise you that as of the date hereof, the
Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a
Ichor Corporation) (the "CORPORATION"), which administers the Mymetics
Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to
purchase 75,000 shares of Common Stock (the "COMMON STOCK") of the Corporation
at a price of $0.14 per share (the "OPTION"). A summary of all options that have
been granted to you (including the Options) under the Plan is set forth on
Exhibit A, attached hereto.

         The terms applicable to the Option are set forth below and in the Plan,
a copy of which accompanies this Agreement.

1.       Term and Vesting.

         The Option shall expire at the close of the business on July 31, 2013.
The Option granted hereby shall be fully vested as of the date of this Stock
Option Agreement

2.       Other Option Terms.

         The Option has been granted pursuant to the Plan, and the terms and
conditions of the Plan are incorporated by reference in this Agreement as though
set forth herein in their entirety.

<PAGE>

         The Option is a "Non-Statutory Stock Option" as defined in the Plan.

         If your relationship with the Corporation (or a Subsidiary) terminates
for a reason other than death, voluntary termination with the written consent of
the Corporation (or a Subsidiary) or involuntary termination without cause, the
Option shall terminate immediately. If your relationship with the Corporation
terminates because of death, voluntary termination with written consent of the
Corporation (or a Subsidiary) or involuntary termination without cause, the
Option shall be exercisable to the extent permitted by Section 7 of the Plan;
provided, however, that if you engage in the operation or management of a
business (whether as owner, partner, officer, director, employee or otherwise)
which is in competition with the Corporation (or a Subsidiary), the
Administrator in its sole discretion may immediately terminate the Option.

         Subject to the foregoing and the provisions of the Plan, the Option may
be exercised at your election, in whole or in part, at any time prior to its
expiration. The Option may be exercised by (a) delivery of written notice to the
Corporation setting forth your election to exercise and the number of shares of
Common Stock to be purchased and (b) payment of the purchase price for the
shares to be purchased. The notice must be dated and signed by the person
exercising the Option. If the Option is exercised by someone other than you, the
notice must be accompanied by proof, satisfactory to the Administrator, of the
right of such person(s) to exercise the Option under the Plan.

         The date of exercise of the Option is the date on which the notice of
exercise, proof of right to exercise (if required) and payment of the exercise
price are received by the Corporation at its principal executive office, to the
attention of the Corporation's Secretary. As of the date of exercise, you will
be considered by the Corporation for all purposes to be the owner of the shares
of Common Stock purchased, subject to the terms set forth in this Agreement.

3.       Securities Law Matters.

         Neither this Option nor the shares of Common Stock issuable upon
exercise of the Option (the "SHARES") have been registered under the Securities
Act of 1933 (the "1933 ACT") or any other securities laws (together with the
1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts,
notwithstanding anything else in the Option to the contrary, you (and any
successive holder) agree by accepting the Option as follows: This Option and the
Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts applicable to the Option
or the Shares or (ii) the availability of an exemption from the registration
requirements of the Acts and, at the reasonable request of the Corporation, an
opinion of counsel reasonably satisfactory to the Corporation that registration
is not required under the Acts.

<PAGE>

         The Corporation is under no obligation to register the Option or the
Shares, or take any other action in connection with the offer or sale of the
Shares.

         Prior to the issuance or delivery of any Shares pursuant to the
exercise of the Option in whole or in part, you may be required to represent and
warrant (i) that the Shares to be acquired upon exercise of the Option are being
acquired for investment for your own account and not with a view to resale or
other distribution thereof and (ii) that you will not sell or otherwise transfer
any such Shares unless the Shares are registered under the Acts or an exemption
from registration is available. The certificate or certificates representing any
Shares issued or delivered upon exercise of the Option shall bear a legend to
this effect (and a legend evidencing any other restrictions on transfer set
forth in the Plan) and other legends required by any applicable securities laws.

4.       Other Transfer Restrictions.

         The Option may not be transferred except as permitted under the Plan.

5.       Tax and Withholding Matters.

         Under current federal income tax laws, upon exercise of the Option you
may recognize compensation income equal to the amount (if any) by which the fair
market value (on the date of exercise) of the Shares acquired upon such exercise
exceeds the purchase price paid for such Shares. You will be notified by the
Corporation of the amount of any state and local income taxes and employment
taxes required to be withheld by the Corporation on any compensation income
resulting from the exercise of the Option, and the Corporation in its sole
discretion may require you to provide the funds necessary to satisfy such
withholding obligation or may provide such funds on your behalf, subject to your
obligation, which you hereby assume, to reimburse the Corporation for the amount
(or portion of the amount) so withheld.

6.       Miscellaneous.

         When accepted by you, this Agreement shall constitute an agreement
which shall be binding upon the successors and assigns of the Corporation and
your heirs and legal representatives.

         This Agreement does not confer any right on you to continue as a
director of the Corporation or any Subsidiary or interfere in any way with the
rights of the Corporation's shareholders to remove you as a director of the
Corporation.

         It is suggested that you obtain competent advice as to the tax
consequences of the exercise of the Option prior to the time you exercise any
part of the Option.

<PAGE>

         This Agreement shall be governed by and construed in accordance with
the laws of the State of Delaware. Any dispute or disagreement which shall arise
under or in any way relate to the interpretation or construction of the Plan or
this Agreement shall be resolved by the Board, and its decision shall be final,
binding and conclusive for all purposes.

         This Agreement is the Stock Option Agreement referred to in Section
7(F) of the Plan and has been prepared in duplicate. Please execute both copies
of this Agreement and the attached Exhibit A in the space provided and return
one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis,
Maryland, Attn: Corporate Secretary.

                                Very truly yours,

                                MYMETICS CORPORATION

                                By: /s/ John M. Musacchio
                                   --------------------------------------------

                                Name: John M. Musacchio
                                     ------------------------------------------

                                Title: Corporate Secretary
                                      -----------------------------------------

Receipt Acknowledged and
Option Accepted:

/s/ Peter P. McCann
---------------------------------------
Signature of Optionee

Print Name: Peter P. McCann
           ----------------------------

DATE:
     ----------------------------------

<PAGE>

                                                                       EXHIBIT A

                        DR. PETER P. MCCANN STOCK OPTIONS

                        (granted as of February 6, 2003)

<TABLE>
<CAPTION>
----------------------------------------------------------- ---------------------------- -----------------------------
                     BASIS FOR GRANT                           EXERCISE PRICE/SHARE          NO. OF OPTION SHARES
----------------------------------------------------------- ---------------------------- -----------------------------
<S>                                                                   <C>                         <C>
Initial Director Options (2002)                                        $3.50                         10,000
----------------------------------------------------------- ---------------------------- -----------------------------
Annual Director Options (2002)                                         $3.50                          1,250
----------------------------------------------------------- ---------------------------- -----------------------------
Separation Agreement (2003)                                            $0.14                         75,000
----------------------------------------------------------- ---------------------------- -----------------------------
                                                                                  TOTAL              86,250
----------------------------------------------------------- ---------------------------- -----------------------------

</TABLE>

                                        Acknowledged and agreed:

                                        /s/ Peter P. McCann
                                        ---------------------------------------
                                        Peter P. McCann           Date<PAGE>

                                                                   Exhibit 10.38

                             PATENT PLEDGE AGREEMENT

         THIS PATENT PLEDGE AGREEMENT (this "AGREEMENT"), is made as of November
__, 2002, by MYMETICS, S.A., a corporation formed under the laws of France
("Mymetics S.A."), MYMETICS DEUTSCHLAND GMBH, a German limited liability company
("Mymetics GmbH"), and MYMETICS CORPORATION, a corporation formed under the laws
of the United States of America ("Mymetics Corporation" and together with
Mymetics S.A. and Mymetics GmbH, the "ASSIGNORS"), in favor of MFC MERCHANT BANK
S.A., a Bank organized under the laws of Switzerland (the "ASSIGNEE").

                                   WITNESSETH

         WHEREAS, Mymetics Corporation, the parent company of Mymetics S.A. and
Mymetics GmbH, is party to that certain Credit Facility Agreement (as amended
from time to time, the "CREDIT AGREEMENT"), dated as of July 27, 2000, by and
among Mymetics Corporation (as successor in interest to Hippocampe S.A.) and the
Assignee, providing for the Assignee to make available to the Assignors,
directly or indirectly, certain credit facilities on the terms and conditions
set forth therein; and

         WHEREAS, in accordance with provisions of the Credit Agreement, and as
further consideration for the extension of additional credit to Mymetics
Corporation under the Credit Agreement, which funds have been and will continue
to be used to fund the operations of each of the Assignors, Assignors have
agreed to deliver patent pledge agreements with respect to all currently
existing, pending and newly developed patents to serve as security for the
Obligations (as that term is defined in the Credit Agreement).

         NOW THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereby agree as
follows, with the intent to be legally bound:

         1. As security for the full and timely payment of the Obligations under
the Credit Agreement and the other Loan Documents, the Assignors hereby grant,
assign and convey to the Assignee their entire right, title and interest in and
to the patent applications and patents listed in Exhibit A which is attached
hereto and incorporated herein by this reference, including, without limitation,
all proceeds thereof (for example, license royalties and proceeds of
infringement suits), the right to sue for past, present and future
infringements, all rights corresponding thereto throughout the world and all
reissues, divisions, continuations, renewals, extensions and
continuations-in-part thereof (collectively, the "PATENTS").

<PAGE>

         2.       The Assignors covenant and warrant that:

         (a) The Patents are subsisting and have not been adjudged invalid or
unenforceable, in whole or in part;

         (b) To the best of the Assignors' knowledge, each of the Patents is
valid and enforceable;

         (c) Except as may have already been pledged by the Assignors to the
Assignee, the Assignors are the sole and exclusive owner of the entire and
unencumbered right, title and interest in and to each of the Patents, free and
clear of any liens, charges and encumbrances, including without limitation
pledges, assignments, licenses and covenants by the Assignor not to sue third
persons; and

         (d) Each of the Assignor has the unqualified right to enter into this
Agreement and perform its terms and has entered and will enter into written
agreements with each of its present and future employees, agents and consultants
responsible for generating inventions incident to their employment, agency or
consulting relationship which will enable such Assignor to comply with the
covenants herein contained.

         3. Each of the Assignor agrees that, until all of the Obligations shall
have been satisfied in full , it will not enter into any agreement (for example,
a license agreement) which is inconsistent with such Assignor's obligations
under this Agreement, without the Assignee's prior written consent. Each of the
Assignors acknowledges that it has derived benefits from the funds made
available pursuant to the Credit Agreement and expect to continue to do so until
the Obligations are satisfied.

         4. If, before the Obligations shall have been satisfied in full, any of
the Assignors shall obtain rights to any new patentable inventions, or become
entitled to the benefit of any patent application or patent for any reissue,
division, continuation, renewal, extensions, or continuation-in-part of any
patent or any improvement on any patent worldwide (in addition to the Patents)
or any other intellectual property, the provisions of Section 1 above, shall
automatically apply thereto and such Assignor shall give to the Assignee prompt
notice thereof in writing.

         5. Each of the Assignor authorizes the Assignee to modify this
Agreement by amending Exhibit A to include any future patents and patent
applications which are Patents under Section 4 above.

         6. Unless and until there shall have occurred and be continuing an
Event of Default (as that term is defined in the Credit Agreement), the Assignee
hereby grants to each of the Assignors the exclusive, nontransferable right and
license under the Patents to make, have made for it, use and sell the inventions
disclosed and claimed in the Patents for the Assignors' own benefit and account
and for none other. Each of the Assignors agrees not to sell or assign its
interest in, or grant any sublicense under, the license granted to such Assignor
in this section, without the prior written consent of the Assignee.

                                      2
<PAGE>

         7. If any Event of Default shall have occurred and be continuing, the
Assignors' license under the Patents as set forth in Section 6 above shall
terminate forthwith, and the Assignee shall have, in addition to all other
rights and remedies given it by this Agreement, those allowed by law, and the
rights and remedies of a secured party under applicable federal, state or local
laws as enacted in any jurisdiction in which the Patents may be located and
without limiting the generality of the foregoing, the Assignee may immediately,
without demand of performance and without other notice (except as set forth
below) or demand whatsoever to Assignors, all of which are hereby expressly
waived, and without advertisement, sell at a public or private sale or otherwise
realize upon, the whole or, from time to time any part of the Patents, or any
interest which the Assignors may have therein, and after deducting from the
proceeds of sale or other disposition of the Patents all expenses (including all
reasonable expenses for brokers' fees and legal services), shall apply the
residue of such proceeds toward the payment of the Obligations. Any remainder of
the proceeds after payment in full of the Obligations shall be paid over to the
Assignors pro rata. Notice of any sale or other disposition of the Patents shall
be given to the Assignors at least five (5) days before the time of any intended
public or private sale or other disposition of the Patents is to be made, which
Assignors hereby agrees shall be reasonable notice of such sale or other
disposition. At any such sale or other disposition, Assignee may, to the extent
permissible under applicable law, purchase the whole or any part of the Patents
sold, free from any right of redemption on the part of the Assignors, which
right is hereby waived and released.

         8. If any Event of Default shall have occurred and be continuing, each
of the Assignors hereby authorizes and empowers the Assignee to make, constitute
and appoint any officer or agent of the Assignee, as the Assignee may select in
its exclusive discretion, as such Assignor's true and lawful attorney-in-fact,
with the power to endorse such Assignor's name on all applications, documents,
papers and instruments necessary for Assignee to use the Patents, or to grant or
issue any exclusive or nonexclusive license under the Patents to any third
person, or necessary for Assignee to assign, pledge, convey or otherwise
transfer title in or dispose of the Patents to any third person. Each of the
Assignors hereby ratifies all that such attorney shall lawfully do or cause to
be done by virtue hereof. The Assignors acknowledge that this power of attorney
is coupled with an interest and shall be irrevocable for the life of this
Agreement.

         9. At such time as the Assignors shall completely satisfy all of the
Obligations, this Agreement shall terminate and the Assignee shall execute and
deliver to the Assignors all deeds, assignments and other instruments as may be
necessary or proper to revest in the Assignors full title to the Patents,
subject to any disposition thereof which may have been made by the Assignee
pursuant hereto.

         10. Any and all fees, costs and expenses, including the reasonable
attorney's fees and legal expenses incurred by the Assignee in connection with
the preparation of this Agreement and all other documents relating hereto and
the consummation of this transaction, the filing or recording of any documents
(including all taxes in connection therewith) in public offices, the payment of
discharge of any taxes, counsel fees, maintenance fees, encumbrances or
otherwise protecting, maintaining or preserving the Patents, or in defending or
prosecuting any actions or proceedings arising out of or related to the Patents,
shall be borne and paid to the Assignors on

                                      3
<PAGE>

demand by the Assignee and until so paid shall be added to the principal amount
of the Obligations and shall bear interest at the applicable rate prescribed in
the Credit Agreement.

         11. The Assignors shall have the duty, through counsel acceptable to
the Assignee, to prosecute diligently any patent applications of the Patents
pending as of the date of this Agreement or thereafter until the Obligations
shall have been paid in full, to make application on unpatented but patentable
inventions and to preserve and maintain all rights in patent applications and
patents of the Patents, including without limitation the payment of all
maintenance fees. Any expense incurred in connection with such an application
shall be borne by the Assignor. The Assignors shall not abandon any right to
file a patent application, or any pending patent application or patent without
the consent of the Assignee, which consent shall not be unreasonably withheld.

         12. Each of the Assignors shall have the right, with the consent of the
Assignee, which shall not be unreasonably withheld, to bring suit in its own
name, and to join the Assignee, if necessary, as a party to such suit so long as
the Assignee is satisfied that such joinder will not subject it to any risk of
liability, to enforce the Patents and any license thereunder. The Assignors
shall promptly, upon demand, reimburse and indemnify the Assignee for all
damages, costs and expenses, including legal fees, incurred by the Assignee
pursuant to this section.

         13. No course of dealing between the Assignors and the Assignee, nor
 any failure to exercise, nor any delay in exercising, on the part of the
 Assignee, any right, power or privilege hereunder or under the Credit Agreement
 shall operate as a waiver thereof; nor shall any single or partial exercise of
 any right, power or privilege hereunder or thereunder preclude any other or
 further exercise thereof or the exercise of any other right, power or
 privilege.

         14. All of the Assignee's rights and remedies with respect to the
Patents, whether established hereby or by the Credit Agreement, or by any other
agreements or by law shall be cumulative and may be exercised singularly or
concurrently.

         15. The provisions of this Agreement are severable, and if any clause
or provision shall be held invalid and unenforceable in whole or in part in any
jurisdiction, then such invalidity or unenforceability shall affect only such
clause or provision, or part thereof, in such jurisdiction, and shall not in any
manner affect such clause or provision in any other jurisdiction, or any clause
or provision of this Agreement in any jurisdiction.

         16. This Agreement is subject to modification only by a writing signed
by the parties, except as provided in Section 5 above.

         17. The benefit and burdens of this Agreement shall inure to the
benefit of and be binding upon the respective successor and permitted assigns of
the parties.

         18. This Agreement shall be governed by, construed and enforced in
accordance with, the laws of the State of Delaware.

                                      4
<PAGE>

         19. This Agreement and any amendment hereto may be executed in several
counterparts and by each party on a separate counterpart, each of which, when so
executed and delivered, shall be an original, but all of which together shall
constitute but one and the same instrument. In proving this Agreement or any
amendment hereto, it shall not be necessary to produce or account for more than
one such counterpart signed by the other party against whom enforcement is
sought.

         20. Capitalized terms used in this Agreement as defined terms which are
not defined herein but which are defined in the Credit Agreement shall have the
meanings herein which are given to them in the Credit Agreement.

         21. This Agreement is being made pursuant to the Credit Agreement.
Nothing contained in this Agreement shall in any way supersede, modify, replace,
amend, change, rescind, waive or otherwise affect any of the provisions,
including the representations, warranties, covenants and agreements of the
parties set forth in the Credit Agreement. This instrument is intended only to
effect the transfer of the Patents assigned by the Assignor to the Assignee
pursuant to the Credit Agreement.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                      5
<PAGE>

         IN WITNESS WHEREOF, the Assignor has executed this Agreement as of the
day and year first above written.

                                       MYMETICS CORPORATION

                                       By:
                                           ------------------------------------
                                       Name:
                                             ----------------------------------
                                       Title:
                                              ---------------------------------

                                       By:
                                           ------------------------------------
                                       Name:
                                             ----------------------------------
                                       Title:
                                              ---------------------------------

                                       MYMETICS S.A.

                                       By:
                                           ------------------------------------
                                       Name:
                                             ----------------------------------
                                       Title:
                                              ---------------------------------

                                       By:
                                           ------------------------------------
                                       Name:
                                             ----------------------------------
                                       Title:
                                              ---------------------------------

                                       MYMETICS DEUTSCHLAND GMBH

                                       By:
                                           ------------------------------------
                                       Name:
                                             ----------------------------------
                                       Title:
                                              ---------------------------------

                                       By:
                                           ------------------------------------
                                       Name:
                                             ----------------------------------
                                       Title:
                                              ---------------------------------

<PAGE>

Acknowledged:

MFC MERCHANT BANK S.A.

By:
    -------------------------------------------------
Name:
      -----------------------------------------------
Title:
       ----------------------------------------------

<PAGE>

                                    EXHIBIT A

                                            (a) PATENTS/PATENT APPLICATIONS

I. UNITED STATES

TITLE: METHOD FOR OBTAINING VACCINES FOR PREVENTING THE PATHOGINIC EFFECTS
RELATED TO A RETROVIRAL INFECTION
INVENTORS: SERRES, PIERRE-FRANCOIS;
CURRENT OWNER(S): MYMETICS SA
SERIAL NO.: 09/570921
FILING DATE: 15-May-2000
STATUS: issued September 24, 2002 as US Patent No 6,455,265

TITLE: METHOD FOR OBTAINING VACCINES FOR PREVENTING THE PATHOGINIC EFFECTS
RELATED TO A RETROVIRAL INFECTION
INVENTORS: SERRES, PIERRE-FRANCOIS;
CURRENT OWNER(S): MYMETICS SA
SERIAL NO.: 10/198938
FILING DATE: 22-Jul-2002
STATUS: Pending, filed as divisional of allowed US application  09/570921

TITLE: USE OF ANTIBODIES IDENTIFYING THE INTERLEUKIN-2 RECEPTOR FOR PREVENTING
AND/OR TREATING HIV INFECTIONS
INVENTOR: SERRES, PIERRE-FRANCOIS
CURRENT OWNER(S): MYMETICS SA
SERIAL NO.: 09/979271
FILING DATE: 17-Jan-2002
STATUS: Pending, abandonment in favor of new CIP is under consideration

TITLE:POLYPEPTIDE INHIBITER OF HIV INFECTIVITY
INVENTOR: SERRES, PIERRE-FRANCOIS
CURRENT OWNER(S): MYMETICS CORP
SERIAL NO.: 60/340492
FILING DATE: 18-Dec-2001
STATUS: Pending, this is a US provisional application that will be converted to
US utility and PCT applications by Dec 18, 2002.

<PAGE>

TITLE: POTENT INHIBITION OF HIV-1 IN VITRO BY GP41-DERIVED SYNTHETIC PEPTIDES
INVENTORS: SERRES, PIERRE-FRANCOIS, KAZMI, S H; SATTENTAU, Q J
CURRENT OWNER(S): MYMETICS CORP
SERIAL NO.: 60/386754
FILING DATE: 10-Jun-2002
STATUS: Pending, this is a US provisional application that will be converted to
US utility and PCT applications by June 10, 2003.

TITLE: NEW PEPTIDES AND USE THEREOF IN THERAPEUTIC AGENTS AGAINST FELINE FIVE
INFECTION.
INVENTOR: SERRES, PIERRE-FRANCOIS
CURRENT OWNER(S): MYMETICS SA
SERIAL NO.: 10/222976
FILING DATE: 19-Aug-2002
STATUS: Pending, this is a US utility application based on French applications
01 10910 and 01 15424.

TITLE: PEPTIDES AS INHIBITORS OF HIV INFECTION
INVENTORS: SERRES, PIERRE-FRANCOIS,
CURRENT OWNER(S): MYMETICS CORP
SERIAL NO.: 60/413919
FILING DATE: 27-Jul-2002
STATUS: Pending, this is a US provisional application that will be converted to
US utility and PCT applications by July 27, 2003.

<PAGE>

INTERNATIONAL

INTERNATIONAL FAMILY A:

TITLE: METHOD FOR OBTAINING VACCINES FOR PREVENTING THE PATHOGINIC EFFECTS
RELATED TO A RETROVIRAL INFECTION
INVENTORS: SERRES, PIERRE-FRANCOIS; GEOURJON, CHRISTOPHE; DELEAGE, GILBERT;
COMBET, CHRISTOPHE
CURRENT OWNER(S): HIPPOCAMPE CHANGE TO MYMETICS SA IN PROGRESS
PCT/FR98/02447   WO 99/25377 filed 17-Nov-1998       Published 27-May-1999

<TABLE>
<S>                                          <C>                    <C>
African Regional Industrial                  AP/P/00/01841           filed 17-Nov-1998
Australia                                    12434/99                filed 17-Nov-1998
Brazil                                       PI9814204               filed 17-Nov-1998
Canada                                       2309676                 filed 17-Nov-1998
China                                        98811909.9              filed 17-Nov-1998
Eurasian Patent Organization                 200000528               filed 17-Nov-1998
European Patent Convention                   98955673.3              filed 17-Nov-1998
France                                       9714387                 filed 17-Nov-1997
Israel                                       136163                  filed 17-Nov-1998
Japan                                        2000-520810             filed 17-Nov-1998
Republic of Korean                           2000-7005402            filed 17-Nov-1998
Mexico                                       4633                    filed 17-Nov-1998
New Zealand                                  505152                  filed 17-Nov-1998
African Union Territories OAPI               1200000145              filed 17-Nov-1998
Viet Nam                                     S20000544               filed 17-Nov-1998

</TABLE>

INTERNATIONAL FAMILY B:

TITLE:USE OF ANTIBODIES IDENTIFYING THE INTERLEUKIN-2 RECEPTOR FOR PREVENTING
AND/OR TREATING HIV INFECTIONS
INVENTOR: SERRES, PIERRE-FRANCOIS
CURRENT OWNER(S): HIPPOCAMPE SA CHANGE TO MYMETICS SA IN PROGRESS
PCT/FR00/01399 filed 22-May-2000

<TABLE>
<S>                                          <C>                      <C>
France                                       99/0652                 filed 21-May-1999
  Pending
ARIPO (Africa)                               AP/P/0102354            filed 22-May-2000
  Pending Abandonment under consideration
Canada                                       2373991                 filed 22-May-2000
  Pending
European Patent Convention                   00931335.4              filed 22-May-2000
  Pending
Eurasian Patent Organization                 2001011228              filed 22-May-2000
  Pending  Abandonment under consideration
OAPI (Africa)                                1200100307              filed 22-May-2000
</TABLE>

<PAGE>

<TABLE>
<S>                                          <C>                      <C>
  Pending  Abandonment under consideration
South Africa                                 2001/9664               filed 22-May-2000
  Pending  Abandonment under consideration
</TABLE>

FRENCH APPLICATIONS:

French Application No. 01 10910 (the `910 application), filed August 17, 2001,
novel peptides useful in the treatment of FIV in cats, inventor Pierre-Francois
Serres Pending

French Application No. 01 15424 (the `424 application), filed November 29, 2001,
novel peptides useful in the treatment of FIV in cats, inventor Pierre-Francois
Serres, Pending

French Application No. 01 16290, December 17, 2001. novel peptides useful in the
treatment of FIV in cats, inventor Simone Giannecchini, Pending

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]